Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDActual EPS
CAMP4 Therapeutics Corporation Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2025 | 3 | -$0.78 | -$0.66 | -$0.71 |
| Q2 2025 | 1 | -$0.76 | -$0.76 | -$0.76 |
| Q3 2025 | 1 | -$0.80 | -$0.80 | -$0.80 |
| Q4 2025 | 1 | -$0.73 | -$0.73 | -$0.73 |
| Q1 2026 | 1 | -$0.60 | -$0.60 | -$0.60 |
| Q2 2026 | 1 | -$0.56 | -$0.56 | -$0.56 |
| Q3 2026 | 1 | -$0.58 | -$0.58 | -$0.58 |
| Q4 2026 | 1 | -$0.52 | -$0.52 | -$0.52 |
CAMP4 Therapeutics Corporation Earnings Date And Information
CAMP4 Therapeutics Corporation last posted its earnings results on Thursday, February 27th, 2025. The company reported $-0.76 earnings per share for the quarter, topping analysts' consensus estimates of $-0.82 by $0.06. The company had revenue of 53.63 M for the quarter and had revenue of 186.23 M for the year. CAMP4 Therapeutics Corporation has generated $-3 earnings per share over the last year ($-2.52 diluted earnings per share) and currently has a price-to-earnings ratio of -2.08. CAMP4 Therapeutics Corporation has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 26th, 2025 based on prior year's report dates.
CAMP4 Therapeutics Corporation Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 01/09/2024 | Q3 2024 | -$2.30 | -$2.27 | 0.03 | $56.20 M | $53.63 M |
| 10/10/2023 | Q2 2024 | N/A | -$0.11 | N/A | N/A | $61.71 M |
| 07/10/2023 | Q1 2024 | $0.92 | -$0.11 | -1.03 | N/A | $70.89 M |
| 04/27/2023 | Q4 2023 | N/A | -$0.22 | N/A | N/A | $78.51 M |
| 12/20/2022 | Q3 2023 | -$0.09 | -$0.13 | -0.04 | $86.78 M | $78.89 M |
| 09/22/2022 | Q2 2023 | -$0.92 | -$0.21 | 0.71 | N/A | $72.83 M |
| 06/23/2022 | Q1 2023 | -$1.15 | -$0.34 | 0.81 | N/A | $64.73 M |
| 04/28/2022 | Q4 2022 | -$1.38 | -$0.26 | 1.12 | N/A | $68.38 M |
| 12/21/2021 | Q3 2022 | -$0.23 | -$0.32 | -0.09 | $77.56 M | $68.78 M |
| 09/23/2021 | Q2 2022 | N/A | -$0.15 | N/A | N/A | $79.01 M |
| 06/24/2021 | Q1 2022 | N/A | -$0.06 | N/A | N/A | $79.67 M |
| 04/22/2021 | Q4 2021 | $1.15 | -$0.25 | -1.4 | N/A | $81.95 M |
| 12/17/2020 | Q3 2021 | $0.69 | -$0.68 | -1.37 | $82.98 M | $88.01 M |
| 09/24/2020 | Q2 2021 | -$0.46 | -$0.28 | 0.18 | N/A | $83.54 M |
| 06/25/2020 | Q1 2021 | -$0.69 | -$0.42 | 0.27 | N/A | $80.22 M |
| 05/05/2020 | Q4 2020 | N/A | -$1.65 | N/A | N/A | $87.20 M |
| 12/19/2019 | Q3 2020 | $3.45 | -$0.22 | -3.67 | $95.11 M | $96.60 M |
| 09/26/2019 | Q2 2020 | $2.53 | -$0.22 | -2.75 | N/A | $93.24 M |
| 06/27/2019 | Q1 2020 | N/A | -$0.26 | N/A | N/A | $89.07 M |
| 04/30/2019 | Q4 2019 | N/A | $0.33 | N/A | N/A | $84.38 M |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
CAMP4 Therapeutics Corporation Earnings: FAQ's
CAMP4 Therapeutics Corporation has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 26th, 2025 based offlast year's report dates.
In the previous quarter, CAMP4 Therapeutics Corporation (:CAMP) reported $-0.76 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.82 by $0.06.
The conference call for CAMP4 Therapeutics Corporation's latest earnings report can be listened to online.
The conference call transcript for CAMP4 Therapeutics Corporation's latest earnings report can be read online.
CAMP4 Therapeutics Corporation (:CAMP) has a recorded annual revenue of $186.23 M.
CAMP4 Therapeutics Corporation (:CAMP) has a recorded net income of $-93,261,000.CAMP4 Therapeutics Corporation has generated $-2.52 earnings per share over the last four quarters.
CAMP4 Therapeutics Corporation (:CAMP) has a price-to-earnings ratio of -2.08 and price/earnings-to-growth ratio is 0.01.